切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2022, Vol. 16 ›› Issue (06) : 614 -617. doi: 10.3877/cma.j.issn.1674-3946.2022.06.009

论著

同期肝切除联合脾切除在肝癌合并门静脉高压患者中的应用探讨
曹李1, 牛晓峰1, 孟令展1, 李虎1, 于雁宾1, 俞鹏1, 严锦1, 朱震宇1,()   
  1. 1. 100039 北京,解放军总医院第五医学中心肝病学部肝病外科
  • 收稿日期:2022-08-19 出版日期:2022-12-26
  • 通信作者: 朱震宇

Application of simultaneous hepatectomy combined with splenectomy in hepatocellular carcinoma patients with portal hypertension

Li Cao1, Xiaofeng Niu1, Lingzhan Meng1, Hu Li1, Yanbin Yu1, Peng Yu1, Jin Yan1, Zhenyu Zhu1,()   

  1. 1. Department of Hepatology Surgery,Department of Liver Medicine,Fifth Medical Center,General Hospital of PLA,Beijing 100039,China
  • Received:2022-08-19 Published:2022-12-26
  • Corresponding author: Zhenyu Zhu
  • Supported by:
    National Natural Science Foundation of China(92159305)
引用本文:

曹李, 牛晓峰, 孟令展, 李虎, 于雁宾, 俞鹏, 严锦, 朱震宇. 同期肝切除联合脾切除在肝癌合并门静脉高压患者中的应用探讨[J/OL]. 中华普外科手术学杂志(电子版), 2022, 16(06): 614-617.

Li Cao, Xiaofeng Niu, Lingzhan Meng, Hu Li, Yanbin Yu, Peng Yu, Jin Yan, Zhenyu Zhu. Application of simultaneous hepatectomy combined with splenectomy in hepatocellular carcinoma patients with portal hypertension[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2022, 16(06): 614-617.

目的

探讨肝癌合并门静脉高压伴食管静脉曲张破裂出血的患者同期行肝癌切除和脾切除的安全性及可行性。

方法

回顾性分析2002年1月至2018年1月期间42例肝癌合并门静脉高压伴食管静脉曲张破裂出血行肝脾联合切除患者的临床资料。记录手术时间、术中出血量及术后并发症发生例数。采用门诊复查或电话随访方式随访,随访截至时间为2022年1月。

结果

开腹联合切除33例(78.6%),腹腔镜联合切除9例(21.4%)。其中8例行同期肝切除合并脾切除(19.0%),34例行同期肝切除合并脾切除同时加做贲门周围血管离断(81.0%)。术中出血量(771.4±500.2)ml,术中均未行肝门阻断;手术时间(5.6±2.6)h;42例患者术后病理学检查均证实为肝细胞癌。术后无围手术期临床死亡病例;术后3~6 d均恢复正常饮食。术后发生门脉系统血栓形成最为常见,共计出现32例(76.2%),单侧或者双侧胸腔积液21例(50.0%),肝周或者脾窝脓肿形成3例(7.1%),胆瘘2例(4.8%),严重门脉及脾静脉血栓形成致持续高胆红素血症1例(2.4%),后介入行肠系膜上动脉置管行肝素钠及尿激酶溶栓后好转。术后随访<5个月的3例(7.1%),超过1年的患者39例(92.9%),超过5年的患者9例(21.0%)。其中17例肿瘤复发或转移,并行进一步治疗(40.5%);13例复查胃镜出现不同程度食管静脉曲张(31.0%)。

结论

对于肝癌合并门静脉高压伴脾功能亢进及食管静脉曲张破裂出血的患者,可选择行肝脾联合切除,具有一定的安全性和可行性。

Objective

To investigate the safety and feasibility of hepatectomy and splenectomy in patients with hepatocellular carcinoma complicated with portal hypertension and esophageal varices rupture and hemorrhage.

Methods

From January 2002 to January 2018,the clinical data of 42 patients with hepatocellular carcinoma complicated with portal hypertension and esophageal varices rupture and hemorrhage who underwent hepatosplenectomy were retrospectively analyzed. The operation time,intraoperative blood loss and postoperative complications were recorded. The patients were followed up by outpatient review or telephone follow-up until January 2022.

Results

33 cases(78.6%)underwent laparotomy and 9 cases(21.4%)underwent laparoscopy. Among them,8 patients underwent simultaneous hepatectomy combined with splenectomy(19.0%),and 34 patients underwent simultaneous hepatectomy combined with splenectomy combined with pericardial devascularization(81.0%). The intraoperative blood loss was(771.4±500.2)ml. No hilar block was performed during the operation. The operation time was(5.6±2.6)hours. All 42 patients were confirmed to be hepatocellular carcinoma by postoperative pathological examination. There was no perioperative clinical death. All patients returned to normal diet 3 to 6 days after operation. Postoperative portal vein thrombosis was the most common occurrence,including 32 cases(76.2%),21 cases(50.0%)of unilateral or bilateral pleural effusion,3 cases(7.1%)of perihepatic or splenic fossa abscess,2 cases(4.8%)of bile leakage,1 case(2.4%)of persistent hyperbilirubinemia caused by severe portal vein and splenic vein thrombosis. After intervention,superior mesenteric artery catheterization and thrombolysis with heparin sodium and urokinase improved. Three patients(7.1%)were followed up for less than 5 months,39 patients(92.9%)were followed up for more than 1 year,and 9 patients(21.0%)were followed up for more than 5 years. Among them,17 cases had tumor recurrence or metastasis and received further treatment(40.5%). 13 cases(31.0%)had esophageal varices of varying degrees.

Conclusion

For patients with hepatocellular carcinoma complicated with portal hypertension,hypersplenism and esophageal varices rupture and bleeding,combined hepatosplenectomy can be selected,which has certain safety and feasibility.

表1 42例肝癌合并门静脉高压同期行脾切除联合肝切除患者基本情况
表2 42例肝癌合并门静脉高压同期行脾切除联合肝切除患者手术方式及术后并发症情况
[1]
Rich NEJohn BVParik ND,et al. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi‐center cohort of patients with cirrhosis[J]. Hepatology202072(5):1654-1665.
[2]
中国医师协会器官移植医师分会,中华医学会器官移植学分会. 中国肝癌肝移植临床实践指南(2018版)[J]. 临床肝胆病杂志201935(2):275-280.
[3]
齐瑞兆,史宪杰,李志伟,等. 门静脉高压症上消化道出血不同指南诊治共识外科部分的比较分析[J]. 临床外科杂志201927(1):62-66.
[4]
何伟,李斌奎,元云飞. 肝细胞癌合并门静脉高压症治疗的争议[J/CD]. 中华肝脏外科手术学电子杂志20198(2):87-90.
[5]
乌吉斯古楞. 脾切除贲门周围血管离断术在老年原发性肝癌相关门静脉高压主治疗中的应用[J/CD]. 中华普外科手术学杂志(电子版)201913(1):73-76.
[6]
中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版)[J]. 中国实用外科杂志201939(12):1241-1247.
[7]
党晓卫,张中杰,李路豪. 门静脉高压症性脾功能亢进的处理方式选择[J/CD]. 中华肝脏外科手术学电子杂志20198(3):276-278.
[8]
齐瑞兆,赵新,王胜智,等. 1118例开腹脾切除断流术治疗门静脉高压症术后并发症及生存分析[J]. 中华外科杂志201856(6):436-441.
[9]
Kong JShen SWang W. Synchronous hepatectomy and splenectomy vs hepatectomy for selected patients with hepatocellular carcinoma and clinically significant portal hypertension:A systematic review and meta-analysis[J]. J Surg Oncol2019119(7):964-973.
[10]
付雍,杨广顺. 肝癌合并门静脉高压症的外科治疗[J]. 外科理论与实践201621(5):378-381.
[11]
徐锋,戴朝六,薛建,等. 肝癌切除联合脾切除治疗肝细胞癌合并脾功能亢进的体会[J]. 中国普外基础与临床杂志201421(4):473-475.
[12]
Xie XLLiu XOu J. Is synchronous hepatectomy and splenectomy superior to hepatectomy alone for selected patients with hepatocellular carcinoma and clinically significant portal hypertension?[J]. J Surg Oncol2019120(2):964-973.
[13]
Pei YChai SZhang Y,et al. Benefits of Splenectomy and Curative Treatments for Patients with Hepatocellular Carcinoma and Portal Hypertension:a Retrospective Study[J]. J Gastrointest Surg201923(11):2151-2162.
[14]
Zhang QLi QShang F,et al. The Benefits of Radical Treatments with Synchronous Splenectomy for Patients with Hepatocellular Carcinoma and Portal Hypertension[J]. Cancers(Basel)202214(13):3155.
[15]
贾守洪,鲁旭,彭彬. 多措施联合的腹腔镜肝切除术治疗肝癌合并肝硬化并门静脉高压症的临床应用研究[J/CD]. 中华普外科手术学杂志(电子版)202014(6):569-572.
[1] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[2] 钟锴, 蒋铁民, 张瑞青, 吐尔干艾力·阿吉, 邵英梅, 郭强. 加速康复外科在肝囊型棘球蚴病肝切除术中的应用分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 425-429.
[3] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[4] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[5] 冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[6] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[7] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[8] 杭轶, 杨小勇, 李文美, 薛磊. 可控性低中心静脉压技术在肝切除术中应用的最适中心静脉压[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 813-817.
[9] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[10] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[11] 焦振东, 惠鹏, 金上博. 三维可视化结合ICG显像技术在腹腔镜肝切除术治疗复发性肝癌中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 859-864.
[12] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[13] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[14] 林小勇, 张兰霞, 曾庆劲, 贺需旗, 谭雷, 郭光辉, 龙颖琳, 李凯, 吴宇轩. 负压抽吸活检针在肝困难病灶活检中的初步应用研究[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 694-698.
[15] 雷永琪, 刘新阳, 杨黎渝, 铁学宏, 俞星新, 耿志达, 刘雨, 陈政良, 惠鹏, 梁英健. 肝脏血管周上皮样细胞肿瘤合并贫血一例并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 710-718.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?